阅读说明：本技术 一种具有美白作用的组合物 (Composition with whitening effect ) 是由 陈秋平 林心健 沈健 戚向阳 于 2019-11-13 设计创作，主要内容包括：本发明涉及一种具有美白作用的组合物,其特征在于：包括二氢杨梅素及杨梅苷,所述二氢杨梅素与杨梅苷的摩尔比为(0.01～100):1。本发明将二氢杨梅素与杨梅苷配合使用,二氢杨梅素能够显著增强杨梅苷对黑色素瘤细胞B16F10的增殖作用,抑制酪氨酸酶的活性,从而抑制黑色素的生成,起到美白作用。(The invention relates to a composition with a whitening effect, which is characterized in that: comprises dihydromyricetin and myricitrin, wherein the molar ratio of the dihydromyricetin to the myricitrin is (0.01-100) to 1. According to the invention, the dihydromyricetin and myricitrin are used in a matching manner, and the dihydromyricetin can remarkably enhance the proliferation effect of myricitrin on melanoma cells B16F10 and inhibit the activity of tyrosinase, so that the generation of melanin is inhibited, and the whitening effect is achieved.)

1. A composition with whitening effect is characterized in that: comprises dihydromyricetin and myricitrin, wherein the molar ratio of the dihydromyricetin to the myricitrin is (0.01-100) to 1.

2. The composition with whitening effect according to claim 1, characterized in that: the composition also comprises a carrier and/or excipient, wherein the carrier and/or excipient is at least one of a filling agent, a binding agent, a wetting agent, a disintegrating agent, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant and a flavoring agent.

3. The composition with whitening effect according to claim 2, characterized in that: the filler is selected from starch, lactose, microcrystalline cellulose.

4. The composition with whitening effect according to claim 2, characterized in that: the binder is selected from cellulose derivatives, alginates, gelatin, polyvinylpyrrolidone.

5. The composition with whitening effect according to claim 2, characterized in that: the disintegrating agent is selected from carboxymethyl starch sodium, hydroxypropyl cellulose, cross-linked carboxymethyl cellulose, agar, calcium carbonate, and sodium bicarbonate.

6. The composition with whitening effect according to claim 2, characterized in that: the surfactant is cetyl alcohol or sodium dodecyl sulfate.

7. The composition with whitening effect according to claim 2, characterized in that: the lubricant is selected from pulvis Talci, magnesium stearate, calcium stearate, silica gel micropowder, and polyethylene glycol.

8. The composition with whitening effect according to any one of claims 2 to 7, wherein: the dihydromyricetin, myricitrin and carrier and/or excipient can be made into tablet, capsule, dripping pill, or granule.

9. The composition with whitening effect according to any one of claims 1 to 7, wherein: the mixture of dihydromyricetin and myricitrin is directly extracted from Ampelopsis grossedentata.

10. The composition with whitening effect according to claim 9, characterized in that: the method for extracting dihydromyricetin and myricitrin from vine tea comprises

Placing the ampelopsis grossedentata into an ethanol water solution for ultrasonic extraction or hot reflux extraction, wherein the weight ratio of the ampelopsis grossedentata to the ethanol water solution is (1:10) - (1:200), extracting for 10 min-120 min, filtering out residues, concentrating under reduced pressure, removing ethanol, crystallizing at low temperature, collecting white crystals, and drying to obtain the mixture of dihydromyricetin and myricitrin.

Technical Field

The invention relates to a composition with a whitening effect.

Background

Influenced by the traditional beautiful idea of 'one white covering three uglas', women have a practical pursuit for whitening. Melanin is a protein existing in the basal layer of skin of each person, and the irradiation of ultraviolet rays can change the melanin to generate a substance for protecting the skin, and then the melanin moves to the skin epidermal layer through cell metabolism layer by layer to form skin problems such as color spots, uneven skin color and the like seen by people. In order to combat the above-mentioned skin problems caused by melanin, whitening is an important daily care process, and the types of whitening drugs and cosmetics in the prior art are various and the mechanisms of action are different.

Dihydromyricetin (3,5,7,3', 4', 5' -hexahydroxy-2, 3-dihydroflavonol, DMY) also known as ampelopsin, fujian tea extract, ampelopsin, etc. is an important member of flavonoid compounds in plants. The compound is obtained by Kotake and Kubota in 1940 through separation from leaf of Ampelopsis grossedentata (Melia azedarach, A. Meliae fola) of Ampelopsis of Vitaceae, and is named ampelopsin, and its structural formula is:

myricitrin (MYT) is a natural polyhydroxy flavonoid compound widely existing in bark and leaves of Myrica rubra of Myricaceae, and also in Ampelopsis grossedentata, and has a structural formula:

dihydromyricetin has multiple peculiar effects of scavenging free radicals, resisting oxidation, resisting thrombus, resisting tumor, diminishing inflammation and the like, myricitrin has the effects of improving microcirculation and resisting oxidation, and both myricitrin and myricitrin are expected to be used for protecting skin and generating good effects, but the two are not reported in documents for improving skin conditions by synergistic use at present.

Disclosure of Invention

The invention aims to solve the technical problem of providing a composition with whitening effect, which can effectively inhibit melanin formation, aiming at the current situation of the prior art.

The technical scheme adopted by the invention for solving the technical problems is as follows: a composition with whitening effect is characterized in that: comprises dihydromyricetin and myricitrin, wherein the molar ratio of the dihydromyricetin to the myricitrin is (0.01-100) to 1.

For the convenience of consumer use, the composition further comprises a carrier and/or excipient, wherein the carrier and/or excipient is at least one of a filler, a binder, a wetting agent, a disintegrating agent, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant and a flavoring agent.

Preferably, the filler is selected from starch, lactose, microcrystalline cellulose.

Preferably, the binder is selected from the group consisting of cellulose derivatives, alginates, gelatin, polyvinylpyrrolidone.

Preferably, the disintegrant is selected from sodium carboxymethyl starch, hydroxypropyl cellulose, cross-linked carboxymethyl cellulose, agar, calcium carbonate, sodium bicarbonate.

Preferably, the surfactant is cetyl alcohol or sodium lauryl sulfate.

Preferably, the lubricant is selected from talc, magnesium stearate, calcium stearate, aerosil, polyethylene glycol.

Preferably, the dihydromyricetin and myricitrin and a carrier and/or an excipient are prepared into any one of tablets, capsules, dripping pills and granules. The tablet can be common tablet, film tablet, enteric coated tablet, etc., and can be prepared by mixing above composition dry powder, adding appropriate amount of diluent selected from starch, dextrin, mannitol, microcrystalline cellulose, appropriate amount of binder selected from water, ethanol, cellulose, starch, gelatin, appropriate amount of disintegrating agent selected from sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, sodium alginate, and appropriate amount of lubricant selected from magnesium stearate, or sodium stearate, or polyethylene glycol, adding sweetener selected from D-xylose, xylitol, maltitol, steviosin, aspartame, sucrose, erythritol, mannitol, aspartame, granulating by conventional wet method, granulating by drying or granulating by dry method, such as coated tablet, coating with film-forming material selected from cellulose and polyethylene glycol, and packaging into sealed bottle or aluminum plastic plate. The capsule can be common capsule, enteric capsule, etc., and can be prepared by adding appropriate adjuvant selected from calcium carbonate, magnesium oxide, silica gel micropowder, etc., appropriate lubricant selected from pulvis Talci, magnesium stearate, glycol ester, and silicone, and appropriate binder selected from mineral oil and edible oil, and appropriate sweetener selected from D-xylose, xylitol, maltitol, steviosin, radix asparagi, sucrose, erythritol, mannitol, and aspartame into dry powder, granulating, filling into capsule, and packaging in sealed bottle or aluminum plastic plate.

In the invention, the mixture of dihydromyricetin and myricitrin is directly extracted from vine tea. The method for extracting dihydromyricetin and myricitrin from vine tea comprises the following steps:

placing the ampelopsis grossedentata into an ethanol water solution for ultrasonic extraction or hot reflux extraction, wherein the weight ratio of the ampelopsis grossedentata to the ethanol water solution is (1:10) - (1:200), extracting for 10 min-120 min, filtering out residues, concentrating under reduced pressure, removing ethanol, crystallizing at low temperature, collecting white crystals, and drying to obtain the mixture of dihydromyricetin and myricitrin.

The mixture of dihydromyricetin and myricitrin directly extracted by the extraction method has reasonable proportion, and can play a good synergistic effect, inhibit melanin generation and improve whitening effect.

Compared with the prior art, the invention has the advantages that: according to the invention, the dihydromyricetin and myricitrin are used in a matching manner, and the dihydromyricetin can remarkably enhance the proliferation effect of myricitrin on melanoma cells B16F10 and inhibit the activity of tyrosinase, so that the generation of melanin is inhibited, and the whitening effect is achieved.

Drawings

FIG. 1 is a graph showing the effect of dihydromyricetin and myricitrin on the inhibition of B16F10 cell proliferation in an example of the present invention;

FIG. 2 is a graph showing the combined effect of dihydromyricetin and myricitrin on the proliferation inhibition of B16F10 cells in the present example;

FIG. 3 is a graph showing the inhibitory effect of dihydromyricetin and myricitrin on tyrosinase activity in B16F10 cells in accordance with an embodiment of the present invention;

FIG. 4 is a graph showing the analysis of the synergistic effect of dihydromyricetin and myricitrin on the tyrosinase activity of B16F10 cells in the present invention.

Detailed Description

The invention is described in further detail below with reference to the accompanying examples.

The composition with whitening effect comprises dihydromyricetin and myricitrin, wherein the molar ratio of the dihydromyricetin to the myricitrin is (0.01-100): 1. For the convenience of consumer use, the composition further comprises a carrier and/or excipient, wherein the carrier and/or excipient is at least one of a filler, a binder, a wetting agent, a disintegrant, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant and a flavoring agent. The specific type and amount of the carrier and/or excipient can be selected according to the requirement.

The filler is selected from starch, lactose, and microcrystalline cellulose. The binder is selected from cellulose derivatives, alginate, gelatin, and polyvinylpyrrolidone. The disintegrating agent is selected from sodium carboxymethyl starch, hydroxypropyl cellulose, cross-linked carboxymethyl cellulose, agar, calcium carbonate, and sodium bicarbonate. The surfactant is cetyl alcohol or sodium dodecyl sulfate. The lubricant is selected from pulvis Talci, magnesium stearate, calcium stearate, silica gel micropowder, and polyethylene glycol. Dihydromyricetin, myricitrin and carrier and/or excipient can be made into tablet, capsule, dripping pill, or granule.

The mixture of dihydromyricetin and myricitrin in the embodiment can be directly extracted from ampelopsis grossedentata, and the method for extracting dihydromyricetin and myricitrin from ampelopsis grossedentata comprises the following steps:

placing the ampelopsis grossedentata into an ethanol water solution for ultrasonic extraction or hot reflux extraction, wherein the weight ratio of the ampelopsis grossedentata to the ethanol water solution is (1:10) - (1:200), extracting for 10 min-120 min, filtering out residues, concentrating under reduced pressure, removing ethanol, crystallizing at low temperature, collecting white crystals, and drying to obtain the mixture of dihydromyricetin and myricitrin.

In this example, in order to verify the efficacy of dihydromyricetin and myricitrin in combination, the monomers of each component were mixed in proportion, and the MTT method and the colorimetric method were used to evaluate the effect of the drug on the activity of melanoma cells and the tyrosinase activity in the cells, and the CI value method was used to analyze the combined effect of the drug. The following materials used in the validation process were:

B16F10 cells were purchased from the shanghai cell bank; dihydromyricetin (standard substance) and myricitrin (standard substance) are purchased from Beijing Soilebao science and technology Co., Ltd; RPMI Medium (AR) was purchased from GE; fetal bovine serum (AR) was purchased from Beijing Quanji Biotech, Inc.; MTT (AR) available from Solebao technologies, Inc., Beijing; trypsin (AR) was purchased from Beijing Quanjin Biotechnology Ltd.

The method for detecting the cell proliferation rate by the MTT method comprises the following steps:

when 80% -90% cell density was reached, cells were plated. Digesting the cells in the culture medium, sucking out the culture medium in a culture dish by a pipette gun, adding 2mL of PBS buffer solution, shaking the culture dish to remove the cells, and discarding waste liquid. Most of the cells were digested by adding 1mL of trypsin, and then the reaction was stopped by adding 2mL of culture medium. Collecting the cells in a centrifuge tube after blowing, centrifuging for 5min at 1000r/min, discarding the supernatant and suspending in RPIM-1640 medium containing 10% FBS, and the steps after centrifuging are as follows: aseptically discarding the supernatant, adding 1-2mL of culture medium containing 10% FBS, continuously blowing with a pipette, pouring into a tank at a rate of 3X 10 per well³Density of individual cells B16F10 cell suspension was seeded in four 96-well plates using a row gun, i.e. 100 μ L of cell suspension per well and 100 μ L of PBS solution around the perimeter, with the cell name and generation number written on the plate. Finally placing the mixture at 37 ℃ and containing 5% CO₂Saturated wetDegree of CO₂An incubator.

After plating, the cells were cultured for 24 hours for administration. Using FBS-free culture solution as a control group, adding prepared medicines into the paved cell plate according to 100uL per hole, writing the names and the concentrations of the medicines on the flat plate, and finally, at the temperature of 37 ℃ and the saturation humidity of 5% CO, adding the prepared medicines into the spread cell plate to obtain a sample group₂CO of₂The culture was carried out in an incubator for 72 hours. The growth and proliferation rate of the cells were measured by the MTT method. To each well, 10. mu.L of MTT was added at 5mg/mL, and the cells were incubated in an incubator for 4 hours and centrifuged at 3000 rpm for 10 min. The medium was carefully aspirated, 150. mu.L of DMSO was added to each well to dissolve and develop the color, and after 10min of light shielding treatment, the absorbance was measured at a wavelength of 570nm with a microplate reader.

Calculation of synergy index (CI):

the synergistic, antagonistic or additive effects of the two drugs were further analyzed by calculation of CI values. Respectively calculating the ED of the drugs in single use and combined use through experimental results₅₀The Combination Index (CI) of the drug is then calculated. If CI is less than 0.9, the synergistic effect is obtained, and the smaller the CI value is, the stronger the synergistic effect is; CI is more than 1.1, and antagonism is achieved; CI is more than or equal to 0.9 and less than or equal to 1.1, and the superposition effect is similar.

The specific verification process is as follows:

20mg of dihydromyricetin is prepared into a 100mM solution by 625 mu L of DMSO, and a sample is diluted to 400 mu M when the dihydromyricetin is used; 20mg of myricitrin was prepared as a 100mM solution in 431. mu.L DMSO, and the sample was diluted to 400. mu.M at the time of use. The diluted dihydromyricetin and myricitrin are combined according to a single factor and 8:1, 4:1, 2:1, 1:2 and 1:4, and an MTT method is used for detecting the inhibition effect of different drug concentrations on the proliferation of the B16F10 cells under the single factor and different proportions.

As shown in figure 1, when DMY, MYT or combination of DMY and MYT are used, the proliferation of B16F10 cells can be inhibited, and the inhibition rate of the cell proliferation is gradually increased along with the increase of the drug concentration, so that the drug concentration shows a dose-dependent effect. When the medicines are used in combination, ED is increased along with the increase of DMY content in the mixed medicines₅₀Gradually decreases, when DMY: MYT is greater than 1:1, ED of the drug combination group₅₀All are lower than single medicine group, wherein when DMY is MYT-8: 1, ED is₅₀At the lowest, 19.94. mu.M (see Table 1). Further adopting CI value analysis experiment results, as shown in figure 2, DMY and MYT have synergistic effect on inhibiting B16F10 cell proliferation, and when the DMY and the MYT are combined according to the proportion of 1: 4-8: 1, ED₂₅、ED₅₀And ED₇₅The CI is less than 1, and the synergistic effect is shown, which indicates that the dihydromyricetin can obviously improve the proliferation inhibition of myricitrin on B16F10 cells when the dihydromyricetin and the dihydromyricetin are used together.

TABLE 1 half inhibitory concentration of different samples on B16F10 proliferation

As shown in figure 3, DMY and MYT can inhibit tyrosine activity of B16F10 cells when administered alone or in combination, and the inhibition of the tyrosine activity is gradually enhanced in a dose-dependent manner with the increase of the drug concentration, wherein the activity of DMY is stronger than that of MYT, and ED of the drug combination group is stronger than that of MYT₅₀All are lower than single medicine group, wherein when DMY is MYT-2: 1, ED is₅₀At the lowest, 62.59. mu.M (Table 2). Further adopting CI value analysis experiment results, as shown in figure 2, DMY and MYT have synergistic effect on inhibiting B16F10 cell proliferation, and when the DMY and the MYT are combined according to the proportion of 1: 4-8: 1, ED₂₅、ED₅₀And ED₇₅CI is less than 1, and synergistic effect is shown, wherein ED₇₅The CI value was minimal, suggesting that the combination of DMY and MYT is more synergistic at higher intracellular tyrosinase inhibition.

TABLE 2 half inhibitory concentrations of DMY and MYT on tyrosinase in B16F10 cells

The results show that the dihydromyricetin is matched with myricitrin, and the dihydromyricetin can remarkably enhance the proliferation effect of myricitrin on melanoma cells B16F10 and inhibit the activity of tyrosinase, so that the generation of melanin is inhibited, and the whitening effect is achieved.